Clinical Lymphoma, Myeloma & Leukemia
IF
3.23
Papers
6,053
Papers 7,454
1 page of 746 pages (7,454 results)
Newest
#1Kareem Midlig (TAU: Tel Aviv University)
#2Regina DraliukH-Index: 1
view all 5 authors...
Source
Source
Source
#1Fuping Wang (BNU: Beijing Normal University)
#2Tian Qiu (Peking Union Medical College)H-Index: 3
Last. Qiong Yang (BNU: Beijing Normal University)H-Index: 25
view all 4 authors...
Summary null null Myelofibrosis (MF) is a BCR-ABL1–negative myeloproliferative neoplasm (MPN) characterized by anemia, extramedullary hematopoiesis, bone marrow fibrosis, splenomegaly, constitutional symptoms and acute myeloid leukemia (AML) progression. Currently, allogeneic haematopoietic stem cell transplantation (AHSCT) therapy is the only curative option for MF patients. However, AHSCT is strictly limited due to the high rates of morbidity and mortality. Janus kinase 2 (JAK2) inhibitor Ruxo...
Source
#1Domenico Albano (University of Brescia)H-Index: 26
#2Francesco Dondi (University of Brescia)H-Index: 3
Last. Francesco Bertagna (University of Brescia)H-Index: 28
view all 8 authors...
ABSTRACT null null Sarcopenia is considered to be a poor prognostic factor for several oncological diseases; however, some promising results for lymphoma are now available. The definition of sarcopenia is mainly based upon muscle strength, quantity or quality and physical performance, but some imaging tools (such as CT) have been introduced to estimate quantitatively the muscle areas as an indirect expression of sarcopenia. Our aim was to perform a systematic review on the prognostic role of “ra...
Source
#1Paolo Caimi (Case Western Reserve University)H-Index: 21
#2Kirit M. Ardeshna (UCL: University College London)H-Index: 24
Last. Mehdi Hamadani (MCW: Medical College of Wisconsin)H-Index: 51
view all 9 authors...
Abstract null null Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of respons...
Source
#1Mansi Shah (RU: Rutgers University)H-Index: 2
#2Alissa Gabel (RU: Rutgers University)
Last. Dennis L. Cooper (RU: Rutgers University)H-Index: 30
view all 6 authors...
Abstract null null Introduction: Due to functional hypogammaglobulinemia, multiple myeloma patients are at increased risk for infection and generally have poorer responses to vaccines. In this study, we examined antibody responses after complete COVID-19 vaccination in patients with plasma cell dyscrasias, most of whom were receiving treatment. null Patients and Methods: Real world study of consecutive patients with multiple myeloma and other plasma cell dyscrasias (PCD) were evaluated after com...
Source
#1Kaitlyn C Dykes (MedStar Georgetown University Hospital)
#2Sameer Desale (MedStar Health)H-Index: 13
Last. Craig M. Kessler (Georgetown University)H-Index: 50
view all 5 authors...
Abstract null null Purpose: Describe graft and overall survival outcomes in multiple myeloma (MM) patients who underwent kidney transplant (KT) compared to the general KT population. null Patients and Methods: The Organ Procurement and Transplantation Network/National United Network for Organ Sharing (OPTON/UNOS) database was analyzed from 1988-2019 with R 4.00 and the 2013-17 United States Renal Data System (USRDS) was surveyed for incidence and mortality of MM ESRD. null Results: USRDS analysi...
Source
#1Eshrak AL-Shaibani (Princess Margaret Cancer Centre)
#2Rhida Bautista (Princess Margaret Cancer Centre)H-Index: 1
Last. Fotios V. Michelis (Princess Margaret Cancer Centre)H-Index: 10
view all 13 authors...
Abstract null null Background: Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for hematological disease however can be complicated by relapse or graft failure (GF), for which second-HCT and donor lymphocyte infusions (DLI) are performed. This study aimed to compare outcomes following the two interventions. null Methods: We retrospectively investigated 89 patients with relapse or GF after first-HCT, 50 (56%) underwent second HCT and 39 (44%) received (DLI), from June ...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.